TG's MS hopeful ublituximab not cost-effective at Ocrevus' price, ICER says in evidence report
ICER on Wednesday reiterated that TG Therapeutics’ ublituximab, a potential new therapy for multiple sclerosis is not cost effective at the price of $55,081 per year — the same price as Roche’s MS drug Ocrevus. The final report was released exactly one week before the PDUFA date for ublituximab.
Ublituximab, formerly a part of the two-drug combo U2 that was before the FDA for blood cancer, had its BLA pulled after a Phase III readout favored the control arm over U2’s other component, called Ukoniq. It is now back before FDA to treat RMS, or relapsing forms of multiple sclerosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
